NCT05753618View on ClinicalTrials.gov

Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy

PHASE4RecruitingINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

April 17, 2023

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Early-stage Breast Cancer
Interventions
DRUG

Granulocyte Colony-Stimulating Factor (G-CSF)

Participants will receive G-CSF injection (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy.

DRUG

Omission of Granulocyte Colony-Stimulating Factor (G-CSF)

Participants will omit the use of G-CSF (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy

Trial Locations (3)

K7L 2V7

RECRUITING

Kingston Health Sciences Centre, Kingston

L1G 2B9

RECRUITING

Lakeridge Health, Oshawa

K1H 8L6

RECRUITING

The Ottawa Hospital Cancer Centre, Ottawa

Sponsors
All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER